Tectonic Therapeutic, Inc. (TECX)
NASDAQ: TECX · Real-Time Price · USD
27.85
+0.44 (1.61%)
Mar 5, 2026, 4:00 PM EST - Market closed
Company Description
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs).
It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines.
The company’s lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin.
It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators.
The company is headquartered in Watertown, Massachusetts.
Tectonic Therapeutic, Inc.
| Country | United States |
| Founded | 2019 |
| IPO Date | Jun 21, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 60 |
| CEO | Alise Reicin |
Contact Details
Address: 490 Arsenal Way, Suite 210 Watertown, Massachusetts 02472 United States | |
| Phone | 339 666 3320 |
| Website | tectonictx.com |
Stock Details
| Ticker Symbol | TECX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001681087 |
| CUSIP Number | 878972108 |
| ISIN Number | US8789721086 |
| Employer ID | 81-0710585 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Alise S. Reicin M.D., Ph.D. | President, Chief Executive Officer, Secretary and Director |
| Dr. Timothy A. Springer M.B.A., Ph.D. | Co-Founder and Independent Director |
| Daniel Lochner M.B.A. | Chief Financial Officer |
| Dr. Marcella Kuhlman Ruddy M.D., M.S. | Chief Medical Officer |
| Dr. Peter McNamara Ph.D. | Chief Scientific Officer |
| Geraldine Peters-Wiles | Senior Vice President of Human Resources |
| Anthony Muslin M.D. | Chief Development Officer |
| Dr. Marc Schwabish Ph.D. | Chief Business Officer |
| John Diener | Senior Vice President of Antibody Engineering and Protein Sciences |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 4, 2026 | 144 | Filing |
| Mar 3, 2026 | 144 | Filing |
| Feb 27, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 27, 2026 | SCHEDULE 13G | Filing |
| Feb 26, 2026 | 8-K | Current Report |
| Feb 26, 2026 | 10-K | Annual Report |
| Feb 24, 2026 | 8-K | Current Report |
| Jan 29, 2026 | SCHEDULE 13G | Filing |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |